Geoffrey von Maltzahn, PhD

Geoffrey von Maltzahn is the Founding Chief Executive Officer of Mirai Bio and a general partner at Flagship Pioneering. He is an inventor, entrepreneur, CEO, and co-founder of multiple groundbreaking companies that integrate biology and data science to transform human health and sustainability.

Geoffrey has co-founded companies that have, in aggregate, achieved over $10 billion in public and private market capitalization. Through his role in Flagship Labs, the company’s innovation foundry, Geoffrey has created companies that include Quotient Therapeutics, Tessera Therapeutics, Generate Biomedicines, Indigo Agriculture, Sana Biotechnology (NASDAQ: SANA), and Seres Therapeutics (NASDAQ: MCRB). Geoffrey currently serves as executive chair of Quotient Therapeutics’ Strategic Oversight board, board chair of Tessera Therapeutics, chief innovation officer and board director of Indigo Agriculture, and board director of Generate Biomedicines.

Geoffrey was awarded a PhD in biomedical engineering and medical physics from MIT under the mentorship of Sangeeta N. Bhatia, MD, PhD; an MS in bioengineering from the University of California, San Diego; and an SB in chemical engineering from MIT.